Answers are grounded in this paper and cite their sources.
Introduction Intra-articular drug delivery faces challenges of rapid clearance and limited efficacy. Mechanically activated microcapsules (MAMCs) offer an innovative approach for sustained release of therapeutics in response to joint loading and mechanical compression during normal movement. Objectives To evaluate the safety and efficacy of MAMCs containing interleukin-1 receptor antagonist (IL-1Ra) in reducing acute joint inflammation compared with soluble IL-1Ra and empty MAMCs in an equine model of induced synovitis. Methods Twelve skeletally mature horses (6M, 6F) received 1 intra-articular injection of IL-1β to induce acute synovitis in 1 middle carpal joint with the contralateral limb serving as control. After 48 hours, joints were randomly assigned to receive empty MAMCs, soluble IL-1Ra, or MAMCs containing IL-1Ra. Lameness, synovial fluid cytokines, and physical examination findings were assessed at baseline and on days 2, 7, 14, and 21. Arthroscopy and biopsies were performed on day 21. Statistical analysis used mixed-effects models and 1-way ANOVA. Results All IL-1β-treated groups developed inflammation and showed progressive clinical improvement over 21 days. The MAMC IL-1Ra group showed the lowest frequency of clinically relevant lameness (11%) compared with soluble IL-1Ra (22%) and empty MAMCs (67%) ( P = .03). By day 14, both IL-1Ra groups showed greater reductions in IL-10 and TNF-α than empty MAMC, with equivalent anti-inflammatory effects between soluble and MAMC IL-1Ra ( P > .05). Arthroscopy and histology showed no cartilage or synovial pathology, and no systemic or local adverse effects. Conclusions MAMC-delivered IL-1Ra demonstrated comparable short-term efficacy and safety relative to soluble IL-1Ra in this acute equine synovitis model.
No takes yet. Share an insight, caveat, or question.
DePhillipo et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: